Evidence map›Paper›PMID 40090768›Full record

ArticleEpidemiology and infection2025

Comparison of two methods for the estimation of COVID-19 vaccine effectiveness of the autumnal booster within the VEBIS-EHR network in 2022/23.

Susana Monge, James Humphreys, Nathalie Nicolay, Toon Braeye, Izaak Van Evercooren, Christian Holm Hansen, Hanne-Dorthe Emborg, Massimo Fabiani, Chiara Sacco, Jesús Castilla and 12 more

Abstract readComparative Study
In one paragraph

Article in Epidemiology and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Susana MongeDepartment of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.ORCID https://orcid.org/0000-0003-1412-3012
James HumphreysDepartment of Epidemiology, Epiconcept, Paris, France.ORCID https://orcid.org/0009-0004-3789-8309
Nathalie NicolayVaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.
Toon BraeyeDepartment of Epidemiology and Public Health, Sciensano, Elsene, Belgium.ORCID https://orcid.org/0000-0002-5637-4613
Izaak Van EvercoorenDepartment of Epidemiology and Public Health, Sciensano, Elsene, Belgium.
Christian Holm HansenDepartment of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.
Hanne-Dorthe EmborgDepartment of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.
Massimo FabianiInfectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy.ORCID https://orcid.org/0000-0002-5893-7117
Chiara SaccoInfectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy.
Jesús CastillaInstituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.ORCID https://orcid.org/0000-0002-6396-7265
Iván Martínez-BazInstituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.ORCID https://orcid.org/0000-0002-3405-2277
Brechje de GierCenter for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.ORCID https://orcid.org/0000-0002-9067-090X
Susan HahnéCenter for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Hinta MeijerinkDepartment of Infection Control and Vaccines, Norwegian Institute of Public Health (NIPH), Oslo, Norway.ORCID https://orcid.org/0000-0002-5898-2778
Anja Bråthen KristoffersenDepartment of Method Development and Analytics, Norwegian Institute of Public Health (NIPH), Oslo, Norway.
Ausenda MachadoDepartamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, LisboaPortugal.ORCID https://orcid.org/0000-0002-1849-1499
Patricia SoaresDepartamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, LisboaPortugal.
Mario Fontán-VelaDepartment of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Anthony NardoneDepartment of Epidemiology, Epiconcept, Paris, France.ORCID https://orcid.org/0000-0003-1138-0937
Esther KisslingDepartment of Epidemiology, Epiconcept, Paris, France.ORCID https://orcid.org/0000-0001-7188-8404
Baltazar NunesDepartment of Epidemiology, Epiconcept, Paris, France.ORCID https://orcid.org/0000-0001-6230-7209
VEBIS-Lot 4 working group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Within an infrastructure to monitor vaccine effectiveness (VE) against hospitalization due to COVID-19 and COVID-19 related deaths from November 2022 to July 2023 in seven countries in real-world conditions (VEBIS network), we compared two approaches: (a) estimating VE of the first, second or third COVID-19 booster doses administered during the autumn of 2022, and (b) estimating VE of the autumn vaccination dose regardless of the number of prior doses (autumnal booster approach). Retrospective cohorts were constructed using Electronic Health Records at each participating site. Cox regressions with time-changing vaccination status were fit and site-specific estimates were combined using random-effects meta-analysis. VE estimates with both approaches were mostly similar, particularly shortly after the start of the vaccination campaign, and showed a similar timing of VE waning. However, autumnal booster estimates were more precise and showed a clearer trend, particularly compared to third booster estimates, as calendar time increased after the vaccination campaign and during periods of lower SARS-CoV-2 activity. Moreover, the decrease in protection by increasing calendar time was more clear and precise than when comparing protection by number of doses. Therefore, estimating VE under an autumnal booster framework emerges as a preferred method for future monitoring of COVID-19 vaccination campaigns.

Indexed as

COVID-19COVID-19 VaccinesImmunization, SecondaryVaccine EfficacyAdultAgedElectronic Health RecordsFemaleHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2SeasonsCOVID-19 Vaccinescohort designCOVID-19electronic health recordshospitalizationmulti-country studySARS-CoV-2vaccine effectiveness

Identifiers

PMID40090768
PMCPMC12001144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.